Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis.
[BACKGROUND] Clinical trials have demonstrated favorable outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
- 95% CI 9.68-12.84
- 연구 설계 meta-analysis
APA
Liang S, Liao W, et al. (2026). Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis.. European journal of clinical pharmacology, 82(2), 30. https://doi.org/10.1007/s00228-025-03949-w
MLA
Liang S, et al.. "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis.." European journal of clinical pharmacology, vol. 82, no. 2, 2026, pp. 30.
PMID
41546725
Abstract
[BACKGROUND] Clinical trials have demonstrated favorable outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). However, significant differences between trial settings and routine clinical practice raise concerns about the real-world prognosis of patients with mTNBC. To address this gap, we conducted the first comprehensive single-arm meta-analysis integrating clinical trials and real-world studies (RWSs) to evaluate clinical outcomes and treatment experiences in mTNBC patients receiving SG.
[METHODS] Relevant studies were searched systematically in seven databases as of November 2024. Clinical trials and RWS of patients receiving SG for mTNBC were included. The primary outcomes of this study were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs).
[RESULTS] The meta-analysis included 1 randomized controlled trial (RCT), 4 single-arm trials and 9 RWSs with a total of 1387 patients. Direct meta-analysis results showed that the overall random-effects pooled prevalence of OS, PFS, and ORR were 11.26 months (95% CI: 9.68-12.84), 4.88 months (95% CI: 4.34-5.41) and 32% (95% CI: 29%-35%) respectively. Clinical study group demonstrated outcomes of OS: 12.93 months (95% CI: 11.51-14.35), PFS: 5.67 months (95% CI: 5.10-6.25), and ORR: 34% (95% CI: 30%-38%), in contrast to RWS group, with OS: 9.7 months (95% CI: 8.63-10.77), PFS: 4.32 months (95% CI: 3.86-4.79), and ORR: 30% (95% CI: 25%-34%). The most common treatment-related adverse events from SG were neutropenia, nausea, anemia and fatigue.
[CONCLUSION] This single-arm analysis aims to compile scientific evidence on SG to provide valuable insights into the management of patients with mTNBC. Further randomized trials to analyze its effectiveness and safety are needed.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024553989.
[METHODS] Relevant studies were searched systematically in seven databases as of November 2024. Clinical trials and RWS of patients receiving SG for mTNBC were included. The primary outcomes of this study were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events (AEs).
[RESULTS] The meta-analysis included 1 randomized controlled trial (RCT), 4 single-arm trials and 9 RWSs with a total of 1387 patients. Direct meta-analysis results showed that the overall random-effects pooled prevalence of OS, PFS, and ORR were 11.26 months (95% CI: 9.68-12.84), 4.88 months (95% CI: 4.34-5.41) and 32% (95% CI: 29%-35%) respectively. Clinical study group demonstrated outcomes of OS: 12.93 months (95% CI: 11.51-14.35), PFS: 5.67 months (95% CI: 5.10-6.25), and ORR: 34% (95% CI: 30%-38%), in contrast to RWS group, with OS: 9.7 months (95% CI: 8.63-10.77), PFS: 4.32 months (95% CI: 3.86-4.79), and ORR: 30% (95% CI: 25%-34%). The most common treatment-related adverse events from SG were neutropenia, nausea, anemia and fatigue.
[CONCLUSION] This single-arm analysis aims to compile scientific evidence on SG to provide valuable insights into the management of patients with mTNBC. Further randomized trials to analyze its effectiveness and safety are needed.
[SYSTEMATIC REVIEW REGISTRATION] https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42024553989.
MeSH Terms
Humans; Triple Negative Breast Neoplasms; Antibodies, Monoclonal, Humanized; Female; Camptothecin; Treatment Outcome; Antineoplastic Agents; Progression-Free Survival; Immunoconjugates
같은 제1저자의 인용 많은 논문 (5)
- Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".
- A tumor-derived mitochondrial tsRNA drives vascular invasion of lung adenocarcinoma by promoting ribosomal assembly in endothelial cells.
- A streamlined technique for in-depth ubiquitomics analysis of formalin-fixed paraffin-embedded tissues.
- Rhein/Fe nanoassembly for triple-negative breast cancer treatment via a ferroptosis and immunogenic death.
- A mechanistic study revealing that SLCO1B3 promotes gastric cancer development and metastasis through MAP1S expression downregulation.